MiniBioReactor Array (MBRA)
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
16
11
2021
accepted:
14
06
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
Antimicrobial drugs are mostly studied for their impact on emergence of bacterial antibiotic resistance, but their impact on the gut microbiota is also of tremendous interest. The MiniBioReactor Array (MBRA) The MBRA preserved each donor's specificities, and differences between the donors were maintained through time. Before treatment, all faecal cultures belonging to the same donor were comparable in composition, richness, and diversity. Treatment with ceftriaxone was associated with a decrease in α-diversity, and an increase in β-diversity index, in a concentration-dependent manner. The maximum effect on diversity was observed after 72 h of treatment. Importantly, one donor had a stronger microbiota β-lactamase activity that was associated with a reduced impact of ceftriaxone on microbiota composition. MBRA can reliably mimic the intestinal microbiota and its modifications under antibiotic selective pressure. The impact of the treatment was donor- and concentration-dependent. We hypothesize these results could be explained, at least in part, by the differences in β-lactamase activity of the microbiota itself. Our results support the relevance and promise of the MBRA system to study drug-microbiota interactions.
Sections du résumé
Background
UNASSIGNED
Antimicrobial drugs are mostly studied for their impact on emergence of bacterial antibiotic resistance, but their impact on the gut microbiota is also of tremendous interest.
Methods
UNASSIGNED
The MiniBioReactor Array (MBRA)
Results
UNASSIGNED
The MBRA preserved each donor's specificities, and differences between the donors were maintained through time. Before treatment, all faecal cultures belonging to the same donor were comparable in composition, richness, and diversity. Treatment with ceftriaxone was associated with a decrease in α-diversity, and an increase in β-diversity index, in a concentration-dependent manner. The maximum effect on diversity was observed after 72 h of treatment. Importantly, one donor had a stronger microbiota β-lactamase activity that was associated with a reduced impact of ceftriaxone on microbiota composition.
Conclusions
UNASSIGNED
MBRA can reliably mimic the intestinal microbiota and its modifications under antibiotic selective pressure. The impact of the treatment was donor- and concentration-dependent. We hypothesize these results could be explained, at least in part, by the differences in β-lactamase activity of the microbiota itself. Our results support the relevance and promise of the MBRA system to study drug-microbiota interactions.
Identifiants
pubmed: 35795241
doi: 10.1093/jacamr/dlac077
pii: dlac077
pmc: PMC9252984
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlac077Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Microbiome. 2021 Mar 22;9(1):66
pubmed: 33752754
Anaerobe. 2012 Apr;18(2):249-53
pubmed: 22155131
J Infect. 2019 Dec;79(6):471-489
pubmed: 31629863
Gut. 2013 Nov;62(11):1591-601
pubmed: 23236009
Antimicrob Agents Chemother. 2003 Nov;47(11):3610-2
pubmed: 14576127
Genome Med. 2016 Apr 13;8(1):39
pubmed: 27074706
J Antimicrob Chemother. 2019 Jul 1;74(7):1876-1883
pubmed: 30989197
Proc Biol Sci. 2021 Mar 31;288(1947):20203106
pubmed: 33757361
Benef Microbes. 2018 Sep 18;9(5):725-742
pubmed: 29695182
Scand J Infect Dis. 1985;17(1):77-82
pubmed: 3992209
J Infect Dis. 1989 Aug;160(2):274-80
pubmed: 2788196
J Antimicrob Chemother. 2019 Jan 1;74(Suppl 1):i6-i15
pubmed: 30690540
Clin Pharmacokinet. 2001;40(9):685-94
pubmed: 11605716
Scand J Infect Dis. 1991;23(5):625-33
pubmed: 1767260
Gut Microbes. 2020 Jul 3;11(4):1116-1129
pubmed: 31918607
Nat Rev Immunol. 2016 May 27;16(6):341-52
pubmed: 27231050
Lancet Infect Dis. 2001 Sep;1(2):101-14
pubmed: 11871461
Microb Ecol. 1998 Mar;35(2):180-7
pubmed: 9541554
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
Trends Mol Med. 2016 Jun;22(6):458-478
pubmed: 27178527
Microorganisms. 2020 Feb 17;8(2):
pubmed: 32079318
PLoS One. 2013 Oct 30;8(10):e77772
pubmed: 24204958
J Agric Food Chem. 2013 Oct 16;61(41):9819-27
pubmed: 24028202
Elife. 2020 May 07;9:
pubmed: 32379042
PLoS One. 2013 Nov 25;8(11):e80201
pubmed: 24282523
Science. 2012 Jun 8;336(6086):1262-7
pubmed: 22674330
J Antimicrob Chemother. 1990 Aug;26(2):261-8
pubmed: 2211457
PeerJ. 2017 Nov 16;5:e4017
pubmed: 29158969
Infect Immun. 2014 Jul;82(7):2815-25
pubmed: 24733099
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
ISME J. 2012 Mar;6(3):610-8
pubmed: 22134646
Acta Biochim Pol. 2019 Mar 4;66(1):1-12
pubmed: 30831575
J Antimicrob Chemother. 2013 Aug;68(8):1842-9
pubmed: 23557928
Nature. 2011 Aug 24;476(7361):393-4
pubmed: 21866137
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4516-22
pubmed: 20534432
Nat Med. 2016 Oct 06;22(10):1079-1089
pubmed: 27711063
Gut. 2016 Nov;65(11):1906-1915
pubmed: 27531828
Infection. 1985;13 Suppl 1:S137-9
pubmed: 4055044
Science. 2005 Mar 25;307(5717):1915-20
pubmed: 15790844
Transl Gastroenterol Hepatol. 2019 May 25;4:40
pubmed: 31231707
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31307985
Front Microbiol. 2018 Aug 14;9:1835
pubmed: 30154767
Sci Rep. 2020 Jan 17;10(1):589
pubmed: 31953453
Sci Rep. 2020 May 20;10(1):8358
pubmed: 32433519
Environ Pollut. 2017 Mar;222:1-9
pubmed: 28086130
Eur J Clin Invest. 1988 Jun;18(3):261-6
pubmed: 3138129
Int J Antimicrob Agents. 2015 Jul;46(1):60-5
pubmed: 25979639
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30936104
Trends Biotechnol. 2012 Jan;30(1):17-25
pubmed: 21764163
Science. 2016 Apr 29;352(6285):544-5
pubmed: 27126037
Cell Mol Gastroenterol Hepatol. 2021;11(4):1023-1044
pubmed: 33238220
Annu Rev Food Sci Technol. 2015;6:329-50
pubmed: 25705934
J Clin Microbiol. 2005 Nov;43(11):5588-92
pubmed: 16272491
Antimicrob Agents Chemother. 1991 May;35(5):976-82
pubmed: 1854180
J Hosp Infect. 2021 Jul;113:1-9
pubmed: 33932556
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
J Antimicrob Chemother. 2007 Jul;60(1):83-91
pubmed: 17483547
Oncotarget. 2018 Jul 20;9(56):30919-30935
pubmed: 30112118
Pharmacol Ther. 2016 Aug;164:144-51
pubmed: 27113407
Sci Data. 2019 Feb 05;6:190007
pubmed: 30720800
J Antimicrob Chemother. 2005 Oct;56(4):717-25
pubmed: 16143709
Microbiome. 2015 Sep 30;3:42
pubmed: 26419531
J Antimicrob Chemother. 1982 Sep;10(3):207-15
pubmed: 6292158
PLoS Biol. 2020 Apr 20;18(4):e3000465
pubmed: 32310938
Science. 2003 May 30;300(5624):1404-9
pubmed: 12775833
Nat Rev Drug Discov. 2008 Feb;7(2):123-9
pubmed: 18239669
Microb Ecol. 2014 Apr;67(3):690-9
pubmed: 24402367
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Genomics Proteomics Bioinformatics. 2019 Feb;17(1):39-51
pubmed: 31026582